Loading...
•
Sep 30, 2020
ACADIA Q3 2020 Earnings Report
Reported strong performance driven by continued growth of new prescribers, with more patients benefitting from NUPLAZID® treatment for Parkinson’s disease psychosis.
Key Takeaways
Acadia Pharmaceuticals reported net sales of NUPLAZID® of $120.6 million for the third quarter ended September 30, 2020, a 27% increase compared to $94.6 million for the same period in 2019. The company's net loss for the quarter was $84.7 million, or $0.54 per common share.
NUPLAZID net sales increased by 27% compared to Q3 2019.
The company is on track with its supplemental NDA for the treatment of dementia-related psychosis with a PDUFA date of April 3, 2021.
Acadia acquired CerSci Therapeutics, expanding its clinical pipeline with a non-opioid, acute and chronic pain program.
New clinical analyses of pimavanserin were presented at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) meeting.
ACADIA
ACADIA
ACADIA Revenue by Segment
Revenue by Segment
NUPLAZID Sales Revenue
CapyFin.com Forward Guidance
Acadia reiterates its NUPLAZID net sales guidance of $430 to $450 million. GAAP R&D guidance is increased to $325 to $340 million from the previous range of $265 to $280 million, primarily as a result of the $52.8 million upfront and transaction expenses associated with the acquisition of CerSci Therapeutics. GAAP SG&A guidance is decreased to $385 to $400 million from the previous range of $400 to $420 million. Non-cash stock-based compensation expense guidance is decreased to $80 to $90 million from the previous range of $90 to $100 million. 2020 year-end cash, cash equivalents, and investment securities guidance of $570 to $590 million is unchanged.
Positive Outlook
- NUPLAZID net sales guidance of $430 to $450 million is reiterated.
- GAAP R&D guidance is increased to $325 to $340 million.
- GAAP SG&A guidance is decreased to $385 to $400 million.
- Non-cash stock-based compensation expense guidance is decreased to $80 to $90 million.
- 2020 year-end cash, cash equivalents, and investment securities guidance of $570 to $590 million is unchanged.